Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Highly effective preservation solutions ensuring the safety and protection of personal care products
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The company plans to add 1700 beds by FY27 through the organic route
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
Subscribe To Our Newsletter & Stay Updated